Project Grant R01CA301573
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$674K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research Program (CFDA 93.395), aims to investigate how certain bacteria associated with immune checkpoint inhibitor (ICI) therapies can modulate anti-tumor immunity in melanoma. The $636,222 grant, with a performance period from April 1, 2025 to March 31, 2030, will fund research conducted by the University of Pittsburgh to test whether ICI-associated bacteria can metabolize dietary...
This $127,049.00 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) aims to define the functional and spatial properties of tumor-specific tumor-infiltrating CD8 T cells. Specifically, the project will:
Generate patient-derived xenograft (PDX) murine models of 3 melanoma patient tumors to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T cells needed to exert immune pressure on a heterogeneous tumor like...
This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute to conduct research on targeting a metabolic vulnerability in melanoma. The key objectives are to use genetic and pharmacological approaches to evaluate how reducing the expression of the enzyme PHGDH, combined with dietary serine restriction, can impact melanoma tumor growth in preclinical models. The research aims...
This federal Project Grant award, valued at $154,568 and awarded by the National Cancer Institute (NCI), will support research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The research aims to enhance understanding of how ILC3s modulate adaptive immune responses, which could inform novel combination treatment strategies to improve the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $445,996 to the University of Pittsburgh to conduct research examining how mitigating oxidative stress at telomeres can improve the function of T cells in adoptive cell therapies against cancer.
Specifically, the research aims to determine the role of oxidative damage at telomeres on T cell function, and how protecting telomeres with an antioxidant...
This $369,108 Project Grant awarded by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) funds research by The Broad Institute, Inc. to investigate the therapeutic potential of intentionally inducing resistance to BRAF and MEK inhibitors in melanoma. The goal is to demonstrate that melanoma cancers which develop resistance to these targeted therapies will become more susceptible to lethal MAPK pathway hyperactivation. The research will employ cellular...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research Program (CFDA 93.395), provides $198,103 to New York University School of Medicine to conduct research on understanding and addressing melanoma bone metastasis. The research aims to define the mechanisms by which melanoma cells colonize the skeletal microenvironment and modify the immune response, with a focus on the role of bone metastasis-associated neutrophils. Through preclinical...
This $442,236.00 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund research at the University of Alabama at Birmingham (UAB) to investigate the role of the YTHDF1 RNA-binding protein in promoting melanoma metastasis. The key objectives are to determine how YTHDF1 drives melanoma cell anoikis resistance and suppresses anti-tumor immunity mediated by natural killer cells.
The research will utilize a range of in vitro and in...
This Project Grant award of $103,948.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant aims to investigate how amino acid availability limits the effector function of tumor-infiltrating T-cells and how enhancing amino acid availability can improve the efficacy of immune checkpoint blockade (ICB) therapy. Key objectives include profiling the...